Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery

Ying Jin1,2, Ming Chen2,3 & Xinmin Yu1,4

The present study aims to compare the 7th and the proposed 8th edition of the AJCC/UICC TNM staging system for NSCLC in a cohort of patients from a single institution. A total of 408 patients with NSCLC who underwent radical surgery were analyzed retrospectively. Survivals were analyzed using the Kaplan–Meier method and were compared using the log-rank test. Multivariate analysis was performed by the Cox proportional hazard model. The Akaike information criterion (AIC) and C-index were applied to compare the two prognostic systems with different numbers of stages. The 7th AJCC T categories, the proposed 8th AJCC T categories, N categories, visceral pleural invasion, and vessel invasion were found to have statistically significant associations with disease-free survival (DFS) on univariate analysis. In the 7th edition staging system as well as in the proposed 8th edition, T categories, N categories, and pleural invasion were independent factors for DFS on multivariate analysis. The AIC value was smaller for the 8th edition compared to the 7th edition staging system. The C-index value was larger for the 8th edition compared to the 7th edition staging system. Based on the data from our single center, the proposed 8th AJCC T classification seems to be superior to the 7th AJCC T classification in terms of DFS for patients with NSCLC underwent radical surgery.

Despite screening and treatment progress, Lung cancer remains the leading cause of cancer death in the People’s Republic of China as well as worldwide. In 2015, an estimated 733,300 new cases of lung and bronchial cancer will be diagnosed, and 610,200 deaths are estimated to occur because of the disease1. Studies have shown, the overall 5-year relative survival rate for all lung cancer patients was less than 20%. On contrast, those patients with operable pulmonary tumors experienced more favorable outcomes that their 5-year survival rate ranged from 20% to 70%2.

Accurate evaluation of the tumor stage, including the extent of the pulmonary lesion and lymph node status, is essential for prognostic assessment and decision-making of the stage-specific therapeutic strategy. The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system is the main tumor-staging system used in clinical practice and research for various solid tumors, including lung cancer. Since the first edition published in 1977, every few years, the version of this classification system is updated according to new data3–5.

A new database of 77,156 patients is being used by the International Association for the Study of Lung Cancer (IASLC) now to inform the 8th edition of the TNM classification of lung cancer due to be introduced in the near future, resulting in several changes from the 7th edition, particularly as regards the T categories6. According to the proposed 8th TNM edition, T categories were so redefined in order to improve their prognostic validity7: The T1 is subclassified into T1a (≤1 cm), T1b (>1 to ≤2 cm), and T1c (>2 to ≤3 cm); T2 is subclassified into T2a (>3 to ≤4 cm)

1Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. 2Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, China. 3Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China. 4Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology, Hangzhou, China. Correspondence and requests for materials should be addressed to X.Y. (email: yu_xinm@sina.cn) or M.C. (email: chen_mingm@sina.cn)
and T2b (>4 to ≤5 cm); Tumors greater than 5 to less than or equal to 7 cm is reclassified as T3; Tumors greater than 7 cm is reclassified as T4.

It is unclear at present, whether these changes have significantly improved the prognostic ability. In this study, we aimed to investigate the predictive ability of the forthcoming 8th edition of the AJCC/UICC TNM classification for disease free survival (DFS) and to compare this with the 7th edition in a cohort of patients with NSCLC who underwent radical surgery with curative intent.

Results

Descriptive characteristics. A total of 408 patients were enrolled in this study. Patients’ characteristics are described in Table 1. All patients were of Chinese ethnicity with a male predominance (76.5%). The mean age of diagnosis of NSCLC was 59.9 years (ranging from 30 to 82 years). One hundred and seventy-seven (43.4%) patients received adjuvant chemotherapy (cisplatinum-based doublets) after operation, and among these patients, the mean cycle of chemotherapy is 3.50 (from 1 to 4).

When tumor size was the only consideration, according to the 7th edition AJCC TNM stage, 58 patients (14.2%) were diagnosed as pathologic T1a (⩽2 cm), 93 patients (22.8%) were T1b (>2 cm, ⩽3 cm), 140 patients (34.3%) were T2a (>3 cm, ⩽5 cm), 69 patients (16.9%) were T2b (>5 cm, ⩽7 cm), 48 patients (11.8%) were T3 (>7 cm), and none of the patients were T4. According to the proposed 8th edition AJCC TNM stage, 8 patients (2.0%) were diagnosed as pathologic T1a (⩽1 cm), 50 patients (12.3%) were T1b (>1 cm, ⩽2 cm), 93 patients

| Total N = 408 | Value | 5-y survival, % | Log-rank X² value | P |
|--------------|-------|-----------------|-------------------|---|
| Age          |       |                 |                   |   |
| ≥60          | 224   | (45.1)          | 49                |   |
| <60          | 184   | (54.9)          | 51                |   |
| Gender       |       |                 |                   |   |
| Female       | 96    | (23.5)          | 54                |   |
| Male         | 312   | (76.5)          | 48                |   |
| pN           |       |                 |                   |   |
| 0            | 227   | (55.6)          | 62                |   |
| 1            | 103   | (25.2)          | 41                |   |
| 2            | 78    | (19.1)          | 27                |   |
| Grade        |       |                 |                   |   |
| High         | 169   | (41.4)          | 45                |   |
| Intermediate | 206   | (50.5)          | 52                |   |
| Low          | 33    | (8.1)           | 58                |   |
| Histology    |       |                 |                   |   |
| Adenocarcinoma | 189 | (46.3)    | 52                |   |
| squamous     | 219   | (53.7)          | 48                |   |
| Pleural invasion |       |           | 18.903 <0.001     |   |
| Yes          | 231   | (56.6)          | 42                |   |
| No           | 177   | (43.4)          | 60                |   |
| Vessel invasion |       |                | 9.446 0.002       |   |
| Yes          | 132   | (32.4)          | 41                |   |
| No           | 276   | (67.6)          | 54                |   |
| The 7th T stage |       |                 | 44.450 <0.001     |   |
| T1a (⩽2 cm)  | 58    | (14.2)          | 72                |   |
| T1b (>2 cm, ⩽3 cm) | 93  | (22.8)      | 54                |   |
| T2a (>3 cm, ⩽5 cm) | 140 | (34.3)      | 51                |   |
| T2b (>5 cm, ⩽7 cm) | 69  | (16.9)      | 43                |   |
| T3 (>7 cm)   | 48    | (11.8)          | 21                |   |
| T4           |       |                 |                   |   |
| The 8th T stage |       |                 | 43.398 <0.001     |   |
| T1a (⩽1 cm)  | 8     | (2.0)           | 100               |   |
| T1b (>1 cm, ⩽2 cm) | 50  | (12.5)       | 68                |   |
| T1c (>2 cm, ⩽3 cm) | 93  | (22.8)       | 54                |   |
| T2a (>3 cm, ⩽4 cm) | 93  | (22.8)       | 52                |   |
| T2b (>4 cm, ⩽5 cm) | 47  | (11.5)      | 49                |   |
| T3 (>5 cm, ⩽7 cm) | 69  | (16.9)      | 43                |   |
| T4 (>7 cm)   | 48    | (11.8)          | 21                |   |

Table 1. Patient demographics and results of univariate analysis for disease-free survival.
(22.8%) were T1c (>2 cm, ≤3 cm), 93 patients (22.8%) were T2a (>3 cm, ≤4 cm), 47 patients (11.5%) were T2b (>4 cm, ≤5 cm), 69 patients (16.9%) were T3 (>5 cm, ≤7 cm), 48 patients (11.8%) were T4 (>7 cm).

In addition, in the 8 patients whose lesions <1 cm, the incidence of lymph node metastasis was zero; in the 50 patients whose lesions between 1 cm and 2 cm, the incidence of lymph node metastasis was 20%; in the 93 patients whose lesions between 2 cm and 3 cm, the incidence of lymph node metastasis was 37.6%; in the 93 patients whose lesions between 3 cm and 4 cm, the incidence of lymph node metastasis was 54.9%; in the 47 patients whose lesions between 4 cm and 5 cm, the incidence of lymph node metastasis was 48.9%; in the 69 patients whose lesions between 5 cm and 7 cm, the incidence of lymph node metastasis was 43.5%; in the 48 patients whose lesions >7 cm, the incidence of lymph node metastasis was 66.7%.

Disease-free Survival. Until the last follow-up checkpoint January 31, 2016, 212 patients (52%) were diagnosed with disease relapse or metastases. The median DFS was 52.4 months (ranging from 53.2 to 61.0 months). The 1-year, 2-year, 3-year DFS were 78%, 65%, 57%, respectively. As shown in Fig. 1, the five Kaplan-Meier survival curves did not overlapped each other in accordance with the 7th AJCC system. The seven Kaplan-Meier survival curves did not overlapped each other in accordance with the proposed 8th AJCC system (Fig. 2).

Univariate analysis. Factors that were analyzed are listed in Table 1, the pathologic N stage (P < 0.001), visceral pleural invasion (P < 0.001), vessel invasion (P = 0.002), the pathologic 7th T stage (P < 0.001) as well as the proposed pathologic 8th T stage (P < 0.001) were significantly associated with DFS.

Multivariate analysis. Since both the 7th T stage and the proposed 8th T stage were prognostic factors in the univariate analysis, two separate multivariate models were performed: one including pathologic N stage, visceral pleural invasion, vessel invasion, and the pathologic 7th T stage; the other including pathologic N stage, visceral pleural invasion, vessel invasion, and the proposed pathologic 8th T stage. As shown in Table 2, in the model in accordance with the 7th edition, pathologic N stage (HR = 1.554), pleural invasion (HR = 1.395), and the pathologic 7th T stage (HR = 1.330) were independent prognostic parameters for DFS. Also in the model in accordance with the 8th edition, pathologic N stage (HR = 1.569), visceral pleural invasion (HR = 1.393), and the proposed pathologic 8th T stage (HR = 1.230) were independent prognostic parameters for DFS. Then, the performance of the 7th and the proposed 8th systems were quantified by the likelihood ratio chi-square and AIC. The AIC value was smaller for the proposed 8th edition compared to the 7th edition AJCC TNM staging system, which indicates that the proposed 8th edition has a better prognostic stratification. Then we performed the analysis of concordance index for the two models and the value for the proposed 8th system was larger than the 7th edition, which means it is more informative about patient’s outcome. The results are consistent with the AIC value.

Discussion
The long-term survival of NSCLC after surgical resection is still unsatisfactory due to the high recurrence and metastasis8. Therefore, it is of great importance to identify prognostic factors which may help to stratify lung cancer patients after radical resection and select high-risk patients who should receive aggressive adjuvant treatment. The IASLC database includes large numbers of patients from several countries can serve as a powerful tool to explore the prognostic details about lung cancer.
The seventh edition of the AJCC TNM staging system for lung cancer has served for clinics since 2009. Based on extensive analyses and evidence from a new large international database (a database of 77,156 evaluable patients diagnosed with lung cancer from 1999 to 2010), the IASLC made proposals to inform the 8th edition of the TNM classification of lung cancer with intent to improve lung cancer staging system, allow for more accurate prediction of prognosis, and better guide lung cancer treatment options. The revision for the proposed 8th edition compared to the 7th edition of AJCC TNM staging system consisted of changes in the T descriptors that reclassifies tumor size into the more refined T subgroups, reclassify the classification of tumor involvement of main bronchus regardless of distance from carina, reclassify atelectasis/pneumonitis, reclassify diaphragm invasion and delete mediastinal pleural effusion as a T descriptor, and the subclassification of M1. Since the 7th edition adequately predict the prognosis, the N descriptors remained the same in the forthcoming staging system.

In this paper, we compared the predictive ability of the forthcoming 8th edition of the AJCC/UICC TNM classification for disease free survival (DFS) to the 7th edition in 408 patients with NSCLC who underwent radical surgery with curative intent in our single center. The major finding of our investigation is that both the 7th and proposed 8th edition AJCC staging system identified the T descriptors as the independent prognostic factors for DFS. Although the AIC and C-index values were not obviously different between the two models, the proposed 8th AJCC staging system T descriptors seems to be superior to that in the 7th edition.

Table 2. Two multivariate analysis models of disease free survival according to 7th edition and proposed 8th edition in 408 patients with NSCLC.

| Factors      | 7th edition (−2 log likelihood: 2336.107; AIC value:2342.11) | 8th edition (−2 log likelihood: 2335.824; AIC value: 2341.82) |
|--------------|---------------------------------------------------------------|---------------------------------------------------------------|
|              | HR (95% confidence interval (CI)) P value                    | HR (95% confidence interval (CI)) P value                    |
| (A) 7th T stage | 1.330 (1.174–1.506) <0.001                                   | 1.230 (1.125–1.346) <0.001                                   |
| N stage      | 1.554 (1.315–1.836) <0.001                                   | 1.569 (1.329–1.852) <0.001                                   |
| Pleural invasion | 1.395 (1.034–1.882) 0.029                                   | 1.393 (1.033–1.878) 0.030                                   |
| (B) 8th T stage | 1.330 (1.174–1.506) <0.001                                   | 1.230 (1.125–1.346) <0.001                                   |
| N stage      | 1.554 (1.315–1.836) <0.001                                   | 1.569 (1.329–1.852) <0.001                                   |
| Pleural invasion | 1.395 (1.034–1.882) 0.029                                   | 1.393 (1.033–1.878) 0.030                                   |

Figure 2. Kaplan-Meier estimates of disease-free survival (DFS) according to the proposed 8th edition T stage. The 5-year DFS rates were 100%, 68%, 54%, 52%, 49%, 43% and 21% for patients with T1a (≤1 cm), T1b (>1 cm, ≤2 cm), T1c (>2 cm, ≤3 cm), T2a (>3 cm, ≤4 cm), T2b (>4 cm, ≤5 cm), T3 (>5 cm, ≤7 cm), T4 (>7 cm), respectively. P < 0.001.

The seventh edition of the AJCC TNM staging system for lung cancer has served for clinics since 2009. Based on extensive analyses and evidence from a new large international database (a database of 77,156 evaluable patients diagnosed with lung cancer from 1999 to 2010), the IASLC made proposals to inform the 8th edition of the TNM classification of lung cancer with intent to improve lung cancer staging system, allow for more accurate prediction of prognosis, and better guide lung cancer treatment options. The revision for the proposed 8th edition compared to the 7th edition of AJCC TNM staging system consisted of changes in the T descriptors that reclassifies tumor size into the more refined T subgroups, reclassify the classification of tumor involvement of main bronchus regardless of distance from carina, reclassify atelectasis/pneumonitis, reclassify diaphragm invasion and delete mediastinal pleural effusion as a T descriptor, and the subclassification of M1. Since the 7th edition adequately predict the prognosis, the N descriptors remained the same in the forthcoming staging system.

In this paper, we compared the predictive ability of the forthcoming 8th edition of the AJCC/UICC TNM classification for disease free survival (DFS) to the 7th edition in 408 patients with NSCLC who underwent radical surgery with curative intent in our single center. The major finding of our investigation is that both the 7th and proposed 8th edition AJCC staging system identified the T descriptors as the independent prognostic factors for DFS. Although the AIC and C-index values were not obviously different between the two models, the proposed 8th AJCC staging system T descriptors seems to be superior to that in the 7th edition.

Tumor size is an important prognostic factor for long-term survival in Lung Cancer. Jeffrey PL et al. analyzed a cohort of patients with pathologically confirmed stage IA NSCLC and found that the 5-year survival for patients with tumor size ≤2.0 cm was higher than those with tumor size >2.0 cm (77.2% vs 60.3%, P = 0.03). In a review of 598 patients with stage I tumors, Martini et al. showed that the survival of patients with lesions <1 cm was significantly better than those with tumors >1 cm. In a recently published study, Zhang Yang et al. investigated 2,260 patients with N0M0 NSCLC in the Surveillance, Epidemiology and End Results (SEER) database and found...
that the 5-year OS rates of pathological tumor size \( \leq 1 \) cm, 1–2 cm, 2–3 cm, 3–4 cm, 4–5 cm, 5–7 cm, and >7 cm were 77.8%, 74.1%, 68.2%, 64.5%, 58.7%, 53.2%, and 57.3%, respectively. In contrast to their result, our result revealed a more significant trend toward worse survival with increasing tumor size. In our analysis, 5-year DFS rates of pathological tumor size \( \leq 1 \) cm, 1–2 cm, 2–3 cm, 3–4 cm, 4–5 cm, 5–7 cm, and >7 cm were 100%, 68%, 54%, 52%, 49%, 43%, and 21%, respectively. In our study, the 5-year DFS rate decreased from 100% in tumors \( \leq 1 \) cm to 21% in tumors >7 cm, whereas in their study, the 5-year OS rate dropped from 77.8% to 57.3%. We think the most plausible explanation for this differences was that in their study the included patients with pathological N0M0 NSCLC, which may represent a group of patients with relative better prognosis compared with those with lymph nodes involvement, leading to selection bias and smaller differences in survival between patients with small and large tumors. In addition, in early-stage NSCLC, the DFS is more refined estimate of outcome than OS.

In our results, we did show that the incidence of lymph nodes involvement was higher in large tumors than small tumors: in the patients whose lesions < 1 cm, the incidence of lymph node metastasis was zero; in those whose lesions between 1 cm and 2 cm, the incidence was 20%; in those whose lesions between 2 cm and 3 cm, the incidence was 37.6%; in those whose lesions >7 cm, the incidence was 66.7%. Previous researches reported similar results with ours. Ishida et al.\(^{15}\) reported that the incidence of lymph node metastasis in patients with lesions >2 cm was 38%, for lesions between 1 cm and 2 cm was 17%, and zero in lesions <1 cm. Our result provide further support for the theory that tumor size may reflect malignant behavior and that small lesions do represent early stage disease. It provides some reassurance that it is necessary to further subdivided the T classification as the proposed 8th edition AJCC staging system.

The multivariate analysis also identified visceral pleural invasion and N classification as the independent prognostic factors for DFS. Several studies demonstrated such result. Wu CY et al.\(^{16}\) has established a predictive survival model for survival in patients with NSCLC who received radical resection and identified tumor size, visceral pleural invasion, and patients with lymph node metastasis as independent prognostic factor for DFS. Huang H et al.\(^{17}\) reported that visceral pleural invasion is a size-independent poor prognostic factor in stage I NSCLC patients. In a systemic review and meta-analysis, Jiang L et al.\(^{18}\) showed that visceral pleural invasion together with tumor size has a synergistic effect on survival in node-negative NSCLC. Indeed, the national comprehensive cancer network (NCCN) guideline recommend stage IB NSCLC patients with visceral pleural invasion to consider adjuvant chemotherapy after surgical resection.

There were several limitations in this paper. Firstly, we only analyzed patients with radical surgery, which may not completely reflect the advantages of the 8th edition of the stage system. Secondly, the sample was relative small, and the differences of AIC and C-index between the two models were not obvious. Therefore, in the next study we will gather more data, in the hope that this will allow clearly distinguishing between the two models.

In conclusion, Based on the data from our single center, the proposed 8th AJCC T classification seems to be superior to the 7th AJCC T classification in terms of DFS for patients underwent radical surgery. Further studies with larger number of patients are needed in order to validate the generalizability of the proposed 8th edition AJCC/UICC TNM staging system of lung cancer.

### Methods

#### Patients Enrollment.

Included were patients who underwent radical operation with curative intent from January 1, 2008 to December 31, 2009 at Zhejiang Cancer Hospital, Hangzhou, China for squamous cell carcinoma and adenocarcinoma of the lung. Study protocols were approved by the Ethical Review Community of Zhejiang Cancer Hospital. The requirement of informed consent was waived by the committee as it was a retrospective research. The methods were carried out in accordance with the relevant guidelines. Excluded were patients with tumor size >7 cm, patients with lymph node involvement status, leading to selection bias and smaller differences in survival between patients with small and large tumors. In addition, in early-stage NSCLC, the DFS is more refined estimate of outcome than OS.

Follow up procedures. Postoperatively, patients were followed at regular intervals by chest CT. DFS was defined as the time from the date of surgery to the time of relapse or metastases. Patients who did not relapse or metastases were censored on the day of last follow-up. The last follow-up checkpoint was January 31, 2016.

#### Statistical Analysis.

Statistical analysis was performed using SPSS22.0 package. Statistical significance was defined as when \( P < 0.05 \). Survival rates were analyzed using the Kaplan – Meier method and were compared using the log-rank test. Multivariate analysis was performed by the Cox proportional hazard model. To measure homogeneity of the direct comparison of the two different edition stage systems, the likelihood ratio \( \chi^2 \) test related to the Cox regression model was used. The discriminatory ability and monotonicity of gradient assessments were measured with the linear trend \( \chi^2 \) test of survival curves according to the N classification of the 6th and 7th editions. The Akaike information criterion (AIC) as well as the C-index were applied into the Cox proportional hazard regression model to correct for the potential bias in comparing prognostic systems with different numbers of stages. AIC was defined as follows: AIC \( = -2 \) log maximum likelihood +2 \times (the number of parameters in the model). A smaller AIC value indicated a better model for predicting outcome. C-index were performed using R software (version 3.2.4), and larger C-index value indicated a better model for predicting outcome.

#### References

1. Chen, W. et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians 66, 115–132, doi: 10.3322/caac.21338 (2016).
2. Strand, T. E., Rostad, H., Moller, B. & Norstein, J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 61, 710–715, doi: 10.1136/thx.2005.056481 (2006).
3. Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E. & Murphy, G. P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86, 2436–2446 (1999).

4. Boffa, D. J. & Greene, F. L. Reacting to changes in staging designations in the 7th edition of the AJCC staging manual. Annals of surgical oncology 18, 1–3, doi:10.1245/s10434-010-1427-z (2011).

5. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology 17, 1471–1474, doi:10.1245/s10434-010-0985-4 (2010).

6. Rami-Porta, R. et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 9, 1618–1624, doi:10.1097/JTO.0000000000000534 (2014).

7. Rami-Porta, R. et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 990–1003, doi:10.1097/JTO.0000000000000559 (2015).

8. Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87–108, doi:10.3322/caac.21262 (2015).

9. Giroux, D. J. The IASLC Lung Cancer Staging Project: data elements for the prospective project. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 4, 679–683, doi:10.1097/JTO.0b013e3181a52370 (2009).

10. Asamura, H. et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 1665–1684, doi:10.1097/JTO.0000000000000678 (2015).

11. Eberhardt, W. E. et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 1515–1522, doi:10.1097/JTO.0000000000000673 (2015).

12. Port, J. L. et al. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest 124, 1828–1833 (2003).

13. Martini, N. et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. The Journal of thoracic and cardiovascular surgery 109, 120–129, doi:10.1016/S0022-5223(95)70427-2 (1995).

14. Zhang, Y., Sun, Y. & Chen, H. Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. OncoTargets and therapy 9, 649–653, doi:10.2147/OTT.S89509 (2015).

15. Ishida, T. et al. Strategy for lymphadenectomy in lung cancer three centimeters or less in diameter. The Annals of thoracic surgery 70, 708–713 (1990).

16. Wu, C. Y. et al. Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection. Medicine 94, e2013, doi:10.1097/MD.0000000000002013 (2015).

17. Huang, H., Wang, T., Hu, B. & Pan, C. Visceral pleural invasion remains a size-independent prognostic factor in stage I non-small cell lung cancer. The Annals of thoracic surgery 99, 1130–1139, doi:10.1016/j.athoracsur.2014.11.052 (2015).

18. Jiang, L. et al. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis. Chest 148, 903–911, doi:10.1378/chest.14-2765 (2015).

19. Palmer, C. R. Encyclopedia of biostatistics. Bmj 318, 542 (1999).

Acknowledgements
This work was supported by Wu Jie Ping medical foundation (Grant No. 320.6750.13393).

Author Contributions
Y.J. prepared the manuscript and took responsibility for the statistical analysis; M.C. edited and reviewed the manuscript; X.Y. designed the study and took responsibility for the integrity of the data.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Jin, Y. et al. Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery. Sci. Rep. 6, 33587; doi: 10.1038/srep33587 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016